Dietary Supplement, Mental Health, Seasonal Affective Disorder, Vitamin D3
Conditions
Keywords
SPAQ, Sigh-SAD, Hamilton 29, Vitamin D3, p25(OH)D
Brief summary
The purpose of this study is to investigate whether vitamin D3 (70 micrograms) is better than placebo in preventing depression symptoms among employees in health care
Detailed description
Vitamin D3 is produced in the skin after exposure to ultraviolet B light from the sun. Vitamin D3 is metabolised sequential in the liver into 25-hydroxy-vitamin D \[25(OH)D\], which is the storage form of vitamin D in the body, and then in the kidney into the steroid hormone, 1a,25-dihydroxyvitamin 1a,25-dihydroxyvitamin D \[1,25(OH)2D\]. At higher latitudes ultraviolet B light is stopped by the atmosphere during winter season. Half of Danes have low levels of \[25(OH)D\] in the blood and especially in the early spring months the levels of \[25(OH)D\] are low. In addition, Vitamin D3 is absorbed through the gut from vitamin D-rich food sources. But several studies show that it is not possible through a recommended diet, which consists of 300 g of fish per week to consume adequate amounts of vitamin D3. New research suggests link between vitamin D3 and brain function.In the Central Nervous System (CNS) there are specific nuclear receptors for 1,25(OH)2D (VDR) and the enzymes necessary for the hydroxylation of 25(OH)D to 1,25(OH)2D are also present in CNS. In clinical studies, low serum levels of 25(OH)D, have been associated with reduced cognitive function, anxiety and depression. The objective of this randomized clinical trial is to investigate whether indoor employees, with tendency to depressive symptoms in the winter season, should be offered vitamin D3 supplements during the Winter season, or it has no significance in relation prevent depressive symptoms. The study is carried out in the winter season in the Region of Southern Denmark for 12 weeks and offered to health service staff, who have a tendency for depressive symptoms in the winter season.
Interventions
70µg Vitamin D3, daily, 12 weeks
Placebo, daily, 12 weeks
Sponsors
Study design
Eligibility
Inclusion criteria
* Health service staff and employee in the Region of Southern Denmark. * Tendency to depressive symptoms in the winter season SPAQ\>7.
Exclusion criteria
* clinical diagnosis sarcoidoses * tuberculosis * bipolar affective disorder * schizophrenia * hypercalcemia * hyperphosphatemia * pregnancy * hyperparathyroidism * reduced kidney function
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton-29 | 12 weeks | Change from baseline in Hamilton-29 at week 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| WHO-5 | 12 weeks | Change from baseline in WHO-5 at week 12 |
Countries
Denmark